Adverse events associated with chemotherapy for common cancers

Area of Science:

• Oncology
• Hematology

Background:

• Neutropenia is a frequent chemotherapy side effect impacting treatment.
• Colony-stimulating factors (CSFs) mitigate neutropenia but are costly and restrictively used.
• Predicting neutropenia risk is challenging, hindering optimal CSF application.

Purpose of the Study:

• To explore methods for predicting chemotherapy-induced neutropenia.
• To discuss the role and efficacy of CSFs in managing neutropenia.
• To review chemotherapy regimen toxicities for better patient stratification.

Main Methods:

• Literature review of primary studies on chemotherapy toxicity.
• Analysis of CSF efficacy and impact on patient outcomes.
• Summarization of toxicity data for common cancer chemotherapy regimens.

Main Results:

• Improved prediction of neutropenia can guide CSF use.
• Understanding regimen-specific toxicities aids in identifying at-risk patients.
• Evidence supports CSF efficacy in reducing neutropenia severity.

Conclusions:

• Better prediction of neutropenia is needed for targeted CSF therapy.
• Knowledge of chemotherapy toxicity can inform clinical decisions.
• Reducing neutropenia occurrence or severity improves patient quality of life.